[Focus on targeting the Ras-MAPK pathway: the Mek inhibitors]

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Context:

• The Ras/Raf/Mek/Erk pathway is integral to tumor progression, influencing cell proliferation, survival, differentiation, and angiogenesis.
• Hyperactivation of this pathway, often due to Kras or Braf mutations, is a significant driver of tumorigenesis.
• Mek inhibitors represent a promising therapeutic strategy for cancers with activated Ras/Raf/Mek/Erk signaling.

Purpose:

• To review the Ras/Raf/Mek/Erk pathway's role in cancer.
• To describe emerging therapeutic strategies targeting this pathway in solid tumors.
• To analyze predictive factors for treatment response and mechanisms of resistance.

Summary:

• The Ras/Raf/Mek/Erk pathway is a critical regulator of cellular processes involved in cancer development.
• Gain-of-function mutations in Kras or Braf frequently lead to pathway hyperactivation, driving tumor growth.
• Mek inhibitors are emerging as targeted therapies for Kras or Braf-mutated cancers, with ongoing research into predictive biomarkers and resistance.

Impact:

• Provides a comprehensive overview of the Ras/Raf/Mek/Erk pathway in oncology.
• Highlights the therapeutic potential of Mek inhibitors in specific cancer types.
• Addresses key challenges in targeted cancer therapy, including response prediction and resistance.